$3.45
-0.14 (-3.90%)
Open$3.64
Previous Close$3.59
Day High$4.00
Day Low$3.43
52W High$11.39
52W Low$3.60
Volume—
Avg Volume23.7K
Market Cap14.82M
P/E Ratio0.08
EPS$45.30
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+824.9% upside
Current
$3.45
$3.45
Target
$31.91
$31.91
$24.67
$31.91 avg
$44.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.33M | 17.69M | 5.44M |
| Net Income | 180.28M | 453.60M | -1,283,535 |
| Profit Margin | 2,848.6% | 2,706.2% | -23.6% |
| EBITDA | -50,836,267 | -135,013,848 | -2,024,078 |
| Free Cash Flow | — | — | -1,099,827 |
| Rev Growth | -64.2% | -64.2% | +18.0% |
| Debt/Equity | 0.08 | 0.08 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |